ReviewNature reviews. Rheumatology2026
Mixed pain phenotypes in musculoskeletal disorders: mechanisms and management.
Review in Nature reviews. Rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pain is categorized into three pain phenotypes: nociceptive, neuropathic and nociplastic, with overlapping pain referring to the coexistence of more than one pain phenotype. Overlapping pain occurs in more than one-third of individuals with musculoskeletal conditions, including inflammatory arthritis, osteoarthritis, spinal disorders and soft-tissue conditions. Whereas nociceptive pain is associated with identifiable tissue pathology and often responds to anatomically focused treatments, the presence of an additional pain phenotype, most commonly nociplastic pain, contributes to clinical complexity, poorer responses to conventional analgesics and procedures, and a greater burden of disease. Clinical identification of overlapping pain relies primarily on history-taking and physical examination, as no validated biomarker or widely accessible diagnostic test is currently available. Quantitative sensory testing and patient-reported questionnaires provide evidence of musculoskeletal overlapping pain but remain underutilized in routine practice. Once the underlying condition has been optimally managed, treatment should adopt a biopsychosocial approach that addresses comorbidities such as psychological distress, promotes self-efficacy and healthy lifestyle behaviours, and incorporates cautious use of pharmacological therapies. Effective clinical care requires recognition of overlapping pain as an important contributor to chronic musculoskeletal pain, with implications for treatment selection, including surgical and interventional decision-making, and for optimizing risk-benefit and cost-effectiveness outcomes.
Identifiers
42888265What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.